Brought to you by 
Alexar formed by NeXeption; raises $21.5mm through its Series A round
27 Feb 2014
Executive Summary
Biopharma management company NeXeption LLC formed Alexar Therapeutics Inc. (dermatology compounds) in conjunction with a $21.5mm Series A venture round. New Science Ventures and Third Point Ventures led (and each contribute one board member) and were joined by Palo Alto Investors.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alexar formed by NeXeption; raises $21.5mm through its Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice